We continue to hear from patients who developed bladder cancer after using Actos for many months or years. We look forward to continued progress in this litigation in the coming year.
New York, New York (PRWEB) January 05, 2013
Actos lawsuits continue to move forward in the federal litigation underway in U.S. District Court, Western District of Louisiana. According to the latest Case Management Order issued in the litigation on January 2, 2012, the Court has established a Periodic Review Process for members of the Plaintiffs’ Steering Committee. The Review Process detailed in the January 2nd Order will afford attorneys in the Actos litigation a means of bringing forward any concerns, comments, or suggestions regarding the administration of the litigation, the Plaintiffs’ Steering Committee, or the Special Master. (In re: Actos Product Liability Litigation, MDL No. 2299).
“We continue to hear from patients who developed bladder cancer after using Actos for many months or years. We look forward to continued progress in this litigation in the coming year,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The firm is currently offering free lawsuit evaluations to individuals who were diagnosed with bladder cancer following long-term use of Actos.
Actos Bladder Cancer Lawsuits
Hundreds of Actos bladder cancer lawsuits are currently pending in the Western District of Louisiana. Plaintiffs allege that individuals who use the type 2 diabetes drug face an increased risk of developing bladder cancer. They further allege that Takeda Pharmaceuticals and other Defendants concealed their knowledge of this risk and failed to provide adequate warnings to consumers and the health care community. According to court documents, the first trial in the federal Actos litigation is scheduled to begin on November 2014, followed by the second trial in July 2015.
Additional Actos claims are also pending in state courts throughout the country. The first trial in the nation is scheduled to begin on February 19, 2013 in a consolidated litigation underway in Los Angeles Superior Court in California. (Jack Cooper, et al. v. Takeda Pharmaceuticals America, Inc., et al., No. CGC-12-518535)
The U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer.* Since then, further research has confirmed an association between Actos and the disease. In May 2012, research published in the British Medical Journal concluded that taking Actos for two years can double the risk of developing bladder cancer. ** A second study published in the Canadian Medical Association Journal in July 2012 concluded that patients taking Actos face a 22 percent increased risk of developing bladder cancer.***
Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP